Safety and Potential Radiosensitizing Effect of Olaparib in Combination With Breast Radiation Therapy for Patients With Triple-Negative Breast Cancer With Residual Disease: Long-Term Results From the RADIOPARP Phase 1 Trial
The RADIOPARP trial demonstrates the long-term safety of combining olaparib with radiation therapy and suggests its potential to enhance locoregional control in HRD tumors. Further studies are warranted to confirm these findings and refine treatment strategies for patients with high-risk TNBC.
Authors
- Jean‐Yves Pierga (ORCID: https://orcid.org/0000-0002-2863-9995)
- Marc‐Henri Stern (ORCID: https://orcid.org/0000-0002-8100-2272)
- Anne Vincent‐Salomon (ORCID: https://orcid.org/0000-0001-5754-5771)
- Frédérique Berger (ORCID: https://orcid.org/0000-0002-3251-4060)
- Pierre Loap (ORCID: https://orcid.org/0000-0001-8863-8110)
- Alain Fourquet
- Kim Cao (ORCID: https://orcid.org/0000-0003-2475-1821)
- Youlia Kirova (ORCID: https://orcid.org/0000-0002-3527-4082)
- Delphine Loirat
Institutions
- Institut Curie (FR)
Publication Details
- Journal
- International Journal of Radiation Oncology*Biology*Physics
- Published
- 2025-05-18
- DOI
- https://doi.org/10.1016/j.ijrobp.2025.05.013
- Citations
- 4
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- AstraZeneca